{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:40:57Z","timestamp":1766050857840,"version":"3.40.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-03656-x","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T15:12:19Z","timestamp":1742310739000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5566-9284","authenticated-orcid":false,"given":"Rog\u00e9rio Serafim","family":"Parra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3256-4698","authenticated-orcid":false,"given":"Renata","family":"de S\u00e1 Brito Fr\u00f3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8180-6254","authenticated-orcid":false,"given":"Daniela Oliveira","family":"Magro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7698-6599","authenticated-orcid":false,"given":"Sandro","family":"da Costa Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7728-6068","authenticated-orcid":false,"given":"Munique Kurtz","family":"de Mello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5487-9418","authenticated-orcid":false,"given":"Matheus Freitas Cardoso","family":"de Azevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7584-7351","authenticated-orcid":false,"given":"Aderson Omar Mour\u00e3o Cintra","family":"Dami\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-7968","authenticated-orcid":false,"given":"Alexandre","family":"de Sousa Carlos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7782-2825","authenticated-orcid":false,"given":"Lu\u00edsa Leite","family":"Barros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-4138","authenticated-orcid":false,"given":"Maria Luiza Queiroz","family":"de Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1858-3446","authenticated-orcid":false,"given":"Andrea","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1449-8386","authenticated-orcid":false,"given":"Marcos Paulo Moraes","family":"Sales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1253-4945","authenticated-orcid":false,"given":"Gilmara Pandolfo","family":"Zabot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0867-6593","authenticated-orcid":false,"given":"Ornella Sari","family":"Cassol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6795-8526","authenticated-orcid":false,"suffix":"Jr","given":"Antonio Jos\u00e9","family":"Tiburcio Alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2779-7841","authenticated-orcid":false,"given":"M\u00e1rcio","family":"Lubini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2266-2542","authenticated-orcid":false,"given":"Marta Brenner","family":"Machado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1623-4525","authenticated-orcid":false,"given":"Cristina","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8915-7279","authenticated-orcid":false,"given":"Fabio Vieira","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0916-4138","authenticated-orcid":false,"given":"Claudio Saddy Rodrigues","family":"Coy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5236-6501","authenticated-orcid":false,"given":"Cyrla","family":"Zaltman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7875-1475","authenticated-orcid":false,"given":"Liliana Andrade","family":"Chebli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7319-8906","authenticated-orcid":false,"given":"Ligia Yukie","family":"Sassaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3593-0526","authenticated-orcid":false,"given":"Omar","family":"F\u00e9res","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1527-0663","authenticated-orcid":false,"given":"J\u00falio Maria Fonseca","family":"Chebli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"issue":"10","key":"3656_CR1","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2023.15389","volume":"330","author":"B Gros","year":"2023","unstructured":"Gros B, Kaplan GG. Ulcerative Colitis in Adults: A Review. JAMA. 2023;330(10):951\u201365. https:\/\/doi.org\/10.1001\/jama.2023.15389.","journal-title":"JAMA"},{"issue":"38","key":"3656_CR2","doi-asserted-by":"publisher","first-page":"5862","DOI":"10.3748\/wjg.v25.i38.5862","volume":"25","author":"RS Parra","year":"2019","unstructured":"Parra RS, Chebli JMF, Amarante HMBS, et al. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil. World J Gastroenterol. 2019;25(38):5862\u201382. https:\/\/doi.org\/10.3748\/wjg.v25.i38.5862.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"3656_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.5152\/tjg.2022.21124","volume":"33","author":"FS da Costa","year":"2022","unstructured":"da Costa FS, Otoboni Aprile LR, Serafim Parra R, et al. Factors Predictive of Proximal Disease Extension and Clinical Course of Patients Initially Diagnosed with Ulcerative Proctitis in an IBD Referral Center. Turk J Gastroenterol. 2022;33(4):320\u20138. https:\/\/doi.org\/10.5152\/tjg.2022.21124.","journal-title":"Turk J Gastroenterol"},{"issue":"11","key":"3656_CR4","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1136\/gutjnl-2023-329964","volume":"72","author":"MF Neurath","year":"2023","unstructured":"Neurath MF, Vieth M. Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healing. Gut. 2023;72(11):2164\u201383. https:\/\/doi.org\/10.1136\/gutjnl-2023-329964.","journal-title":"Gut"},{"key":"3656_CR5","doi-asserted-by":"publisher","unstructured":"Tsai L, Ma C, Dulai PS, et al. Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts. Clin Gastroenterol Hepatol. 2021;19(10):2031\u20132045.e11. https:\/\/doi.org\/10.1016\/j.cgh.2020.10.039","DOI":"10.1016\/j.cgh.2020.10.039"},{"key":"3656_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2147\/BTT.S207246","volume":"13","author":"R Melsheimer","year":"2019","unstructured":"Melsheimer R, Geldhof A, Apaolaza I, Schaible T. Remicade Biologics. 2019;13:139\u201378. https:\/\/doi.org\/10.2147\/BTT.S207246.","journal-title":"Remicade Biologics"},{"key":"3656_CR7","doi-asserted-by":"publisher","unstructured":"Ben-Horin S, Novack L, Mao R, et al. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials. Gastroenterology. 2021. https:\/\/doi.org\/10.1053\/j.gastro.2021.10.037","DOI":"10.1053\/j.gastro.2021.10.037"},{"issue":"1","key":"3656_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12876-022-02280-3","volume":"22","author":"RS Parra","year":"2022","unstructured":"Parra RS, Chebli JMF, Queiroz NSF, et al. Long-term effectiveness and safety of ustekinumab in bio-na\u00efve and bio-experienced anti-tumor necrosis factor patients with Crohn\u2019s disease: a real-world multicenter Brazilian study. BMC Gastroenterol. 2022;22(1):199. https:\/\/doi.org\/10.1186\/s12876-022-02280-3.","journal-title":"BMC Gastroenterol."},{"issue":"7","key":"3656_CR9","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.3390\/jcm12072672","volume":"12","author":"RS Parra","year":"2023","unstructured":"Parra RS, da Costa Ferreira S, Machado VF, et al. Access to High-Cost Biological Agents: Perceptions of Brazilian Patients with Inflammatory Bowel Diseases. J Clin Med. 2023;12(7):2672. https:\/\/doi.org\/10.3390\/jcm12072672.","journal-title":"J Clin Med."},{"issue":"1","key":"3656_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.gastrohep.2020.04.012","volume":"44","author":"A L\u00f3pez-Sanrom\u00e1n","year":"2021","unstructured":"L\u00f3pez-Sanrom\u00e1n A, Esplugues JV, Dom\u00e8nech E. Pharmacology and safety of tofacitinib in ulcerative colitis. Gastroenterol Hepatol. 2021;44(1):39\u201348. https:\/\/doi.org\/10.1016\/j.gastrohep.2020.04.012.","journal-title":"Gastroenterol Hepatol"},{"key":"3656_CR11","doi-asserted-by":"publisher","unstructured":"Perin RL, Magro DO, Andrade AR, et al. Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study. Crohns Colitis 360. 2023;5(1):otac050. https:\/\/doi.org\/10.1093\/crocol\/otac050","DOI":"10.1093\/crocol\/otac050"},{"key":"3656_CR12","doi-asserted-by":"publisher","unstructured":"Sandborn WJ, Lawendy N, Danese S, et al. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0\u00a0years of treatment. Aliment Pharmacol Ther. 2022;55(4):464\u2013478. https:\/\/doi.org\/10.1111\/apt.16712","DOI":"10.1111\/apt.16712"},{"issue":"6","key":"3656_CR13","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gut.2005.082909","volume":"55","author":"J Satsangi","year":"2006","unstructured":"Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749\u201353. https:\/\/doi.org\/10.1136\/gut.2005.082909.","journal-title":"Gut"},{"key":"3656_CR14","doi-asserted-by":"publisher","unstructured":"Naegeli AN, Hunter T, Dong Y, et al. Full, Partial, and Modified Permutations of the Mayo Score: Characterizing Clinical and Patient-Reported Outcomes in Ulcerative Colitis Patients. Crohns Colitis 360. 2021;3(1):otab007. https:\/\/doi.org\/10.1093\/crocol\/otab007","DOI":"10.1093\/crocol\/otab007"},{"issue":"4","key":"3656_CR15","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1093\/ibd\/izac121","volume":"29","author":"MD Long","year":"2023","unstructured":"Long MD, Afzali A, Fischer M, et al. Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting. Inflamm Bowel Dis. 2023;29(4):570\u20138. https:\/\/doi.org\/10.1093\/ibd\/izac121.","journal-title":"Inflamm Bowel Dis"},{"key":"3656_CR16","doi-asserted-by":"publisher","first-page":"175628482110640","DOI":"10.1177\/17562848211064004","volume":"14","author":"LA Lucaciu","year":"2021","unstructured":"Lucaciu LA, Constantine-Cooke N, Plevris N, et al. Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2021;14:17562848211064004. https:\/\/doi.org\/10.1177\/17562848211064004.","journal-title":"Therap Adv Gastroenterol"},{"issue":"2","key":"3656_CR17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.dld.2021.11.009","volume":"54","author":"I Avni-Biron","year":"2022","unstructured":"Avni-Biron I, Bar-Gil Shitrit A, Koslowsky B, et al. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel. Dig Liver Dis. 2022;54(2):192\u20137. https:\/\/doi.org\/10.1016\/j.dld.2021.11.009.","journal-title":"Dig Liver Dis"},{"issue":"7","key":"3656_CR18","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.14309\/ajg.0000000000002145","volume":"118","author":"M Chaparro","year":"2023","unstructured":"Chaparro M, Acosta D, Rodr\u00edguez C, et al. Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety. Am J Gastroenterol. 2023;118(7):1237\u201347. https:\/\/doi.org\/10.14309\/ajg.0000000000002145.","journal-title":"Am J Gastroenterol"},{"key":"3656_CR19","doi-asserted-by":"publisher","unstructured":"Lin CH, Liu WS, Wan C, Wang HH. Effectiveness of tofacitinib in patients with ulcerative colitis: an updated systematic review and meta-analysis of real-world studies. BMJ Open Gastroenterol. 2024;11(1)https:\/\/doi.org\/10.1136\/bmjgast-2024-001347","DOI":"10.1136\/bmjgast-2024-001347"},{"issue":"1","key":"3656_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/ecco-jcc\/jjaa145","volume":"15","author":"M Chaparro","year":"2021","unstructured":"Chaparro M, Garre A, Mesonero F, et al. Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry. J Crohns Colitis. 2021;15(1):35\u201342. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa145.","journal-title":"J Crohns Colitis"},{"key":"3656_CR21","doi-asserted-by":"publisher","unstructured":"Yoon H, Ye BD, Kang SB, et al. Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis: post-marketing surveillance study. BMC Gastroenterol. 2024;24(1):273. https:\/\/doi.org\/10.1186\/s12876-024-03336-2","DOI":"10.1186\/s12876-024-03336-2"},{"issue":"13","key":"3656_CR22","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.3748\/wjg.v30.i13.1871","volume":"30","author":"K Kojima","year":"2024","unstructured":"Kojima K, Watanabe K, Kawai M, et al. Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis. World J Gastroenterol. 2024;30(13):1871\u201386. https:\/\/doi.org\/10.3748\/wjg.v30.i13.1871.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"3656_CR23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.5217\/ir.2023.00194","volume":"22","author":"H Shimizu","year":"2024","unstructured":"Shimizu H, Aonuma Y, Hibiya S, et al. Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study. Intest Res. 2024;22(3):369\u201377. https:\/\/doi.org\/10.5217\/ir.2023.00194.","journal-title":"Intest Res"},{"key":"3656_CR24","doi-asserted-by":"publisher","unstructured":"Sharara AI, Alrazim A, Saniour P, et al. Real world evidence on the effectiveness and safety of tofacitinib in ulcerative colitis in Lebanon. BMC Gastroenterol. 2024;24(1):349. https:\/\/doi.org\/10.1186\/s12876-024-03341-5","DOI":"10.1186\/s12876-024-03341-5"},{"key":"3656_CR25","doi-asserted-by":"publisher","unstructured":"Pan\u00e9s J, D'Haens GR, Sands BE, et al. Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2\u00a0years of drug exposure. United European Gastroenterol J. 2024;12(6):793\u2013801. https:\/\/doi.org\/10.1002\/ueg2.12584","DOI":"10.1002\/ueg2.12584"},{"issue":"1","key":"3656_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/ibd\/izab011","volume":"28","author":"C Taxonera","year":"2022","unstructured":"Taxonera C, Olivares D, Alba C. Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis. Inflamm Bowel Dis. 2022;28(1):32\u201340. https:\/\/doi.org\/10.1093\/ibd\/izab011.","journal-title":"Inflamm Bowel Dis"},{"issue":"18","key":"3656_CR27","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017;376(18):1723\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1606910.","journal-title":"N Engl J Med"},{"issue":"5","key":"3656_CR28","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1093\/ibd\/izad135","volume":"30","author":"T Res\u00e1l","year":"2024","unstructured":"Res\u00e1l T, Bacsur P, Keresztes C, et al. Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study. Inflamm Bowel Dis. 2024;30(5):768\u201379. https:\/\/doi.org\/10.1093\/ibd\/izad135.","journal-title":"Inflamm Bowel Dis"},{"key":"3656_CR29","doi-asserted-by":"publisher","unstructured":"Harindranath S. Tofacitinib in Ulcerative Colitis - Second-Line Therapy, First-Rate Results. Dig Dis Sci. 2024;https:\/\/doi.org\/10.1007\/s10620-024-08589-1","DOI":"10.1007\/s10620-024-08589-1"},{"issue":"8","key":"3656_CR30","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","volume":"21","author":"SR Vavricka","year":"2015","unstructured":"Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21(8):1982\u201392. https:\/\/doi.org\/10.1097\/MIB.0000000000000392.","journal-title":"Inflamm Bowel Dis"},{"key":"3656_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108517","volume":"105","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wan Z, Jin R, et al. Tofacitinib for extraintestinal manifestations of inflammatory bowel disease: A literature review. Int Immunopharmacol. 2022;105: 108517. https:\/\/doi.org\/10.1016\/j.intimp.2022.108517.","journal-title":"Int Immunopharmacol"},{"key":"3656_CR32","doi-asserted-by":"publisher","unstructured":"Colombel JF, Cao Q, Ghosh S, et al. OP33 Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC): Results from the UPA Phase 3 programme. Journal of Crohn's and Colitis. 2022;16(Supplement_1):i036-i037 %@ 1873\u20139946. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab232.032","DOI":"10.1093\/ecco-jcc\/jjab232.032"},{"issue":"1","key":"3656_CR33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10620-020-06177-7","volume":"66","author":"G Syal","year":"2021","unstructured":"Syal G, Robbins L, Kashani A, et al. Hypoalbuminemia and Bandemia Predict Failure of Infliximab Rescue Therapy in Acute Severe Ulcerative Colitis. Dig Dis Sci. 2021;66(1):199\u2013205. https:\/\/doi.org\/10.1007\/s10620-020-06177-7.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"3656_CR34","first-page":"20","volume":"55","author":"NN Mokhele","year":"2017","unstructured":"Mokhele NN, Thomson SR, Watermeyer GA. Predictors of emergency colectomy in patients admitted with acute severe ulcerative colitis. S Afr J Surg. 2017;55(3):20\u20136.","journal-title":"S Afr J Surg"},{"issue":"3","key":"3656_CR35","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/jgh3.12506","volume":"5","author":"M Tanaka","year":"2021","unstructured":"Tanaka M, Takagi T, Naito Y, et al. Low serum albumin at admission is a predictor of early colectomy in patients with moderate to severe ulcerative colitis. JGH Open. 2021;5(3):377\u201381. https:\/\/doi.org\/10.1002\/jgh3.12506.","journal-title":"JGH Open"},{"issue":"10","key":"3656_CR36","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.cgh.2021.05.038","volume":"19","author":"JA Berinstein","year":"2021","unstructured":"Berinstein JA, Sheehan JL, Dias M, et al. Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study. Clin Gastroenterol Hepatol. 2021;19(10):2112-2120.e1. https:\/\/doi.org\/10.1016\/j.cgh.2021.05.038.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3656_CR37","doi-asserted-by":"publisher","unstructured":"Lefevre PLC, Vande Casteele N. Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease. J Crohns Colitis. 2020;14(Supplement_2):S725-S736. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa014","DOI":"10.1093\/ecco-jcc\/jjaa014"},{"issue":"5","key":"3656_CR38","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1007\/s10620-024-08394-w","volume":"69","author":"AM Carvalhas Gabrielli","year":"2024","unstructured":"Carvalhas Gabrielli AM, Ferretti F, Monico CM, et al. Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study. Dig Dis Sci. 2024;69(5):1785\u201392. https:\/\/doi.org\/10.1007\/s10620-024-08394-w.","journal-title":"Dig Dis Sci"},{"key":"3656_CR39","doi-asserted-by":"publisher","unstructured":"Parra RS, Chebli JMF, de Azevedo MFC, et al. Effectiveness and Safety of Ustekinumab for Ulcerative Colitis: A Brazilian Multicentric Observational Study. Crohns Colitis 360. 2024;6(2):otae023. https:\/\/doi.org\/10.1093\/crocol\/otae023","DOI":"10.1093\/crocol\/otae023"},{"issue":"1","key":"3656_CR40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12913-021-07376-2","volume":"22","author":"JAW Cruz","year":"2022","unstructured":"Cruz JAW, da Cunha MAVC, de Moraes TP, et al. Brazilian private health system: history, scenarios, and trends. BMC Health Serv Res. 2022;22(1):49. https:\/\/doi.org\/10.1186\/s12913-021-07376-2.","journal-title":"BMC Health Serv Res."}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03656-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-03656-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03656-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T15:12:22Z","timestamp":1742310742000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-03656-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3656"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-03656-x","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"17 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the coordinating site, the Hospital das Cl\u00ednicas of the Ribeir\u00e3o Preto Medical School at the University of S\u00e3o Paulo, with the following approval details: CAAE 71008923.0.1001.5440; Ethics Committee Number 6.171.795\/2023. Based on this ethical approval, we are authorized to retrospectively collect data from all patients receiving treatment with small molecules, such as tofacitinib. All procedures were conducted in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Parra RS has received fees for serving as a speaker and\/or an advisory board member for Takeda, Janssen, Abbvie, Celltrion and Pfizer. Fr\u00f3es RSB has received fees for serving as a speaker and\/or an advisory board member for Takeda, Janssen, Abbvie, and is a speaker for Celltrion, Nestle, Ferring, Pfizer, and CSL Vifor. Ferreira SC has received fees for serving as a speaker and\/or an advisory board member for Janssen, Takeda, and Pfizer. Mello MK has received fees for serving as a speaker and\/or an advisory board member for Takeda, Janssen, Abbvie, Sandoz and Ferring. Azevedo MFC has received fees for serving as a speaker and\/or an advisory board member for Takeda, Abbvie, Pfizer and Janssen. Dami\u00e3o AOMC has received fees for serving as a speaker and\/or an advisory board member for Takeda, Abbvie, Ferring, and Janssen Carlos AS has received fees for serving as a speaker and\/or an advisory board member for Takeda, Janssen, Abbvie Miranda MLQ has received fees for serving as speaker for Takeda, Janssen and Abbvie Zabot GP has received fees for serving as a speaker and\/or an advisory board member for Janssen, Abbvie, and Takeda. Cassol OS has received fees for serving as a speaker and\/or an advisory board member for Nestle, Abbvie, Janssen, Takeda, and Buhlmann. Alves Junior AJT has received fees for serving as a speaker and\/or an advisory board member for Janssen, Takeda, UCB, and Abbvie. Machado MB has received fees for serving as a speaker and\/or na Advisory board for Takeda, Jassen, Abbvie, Ferring and Pfizer. Teixeira FV is a speaker and an advisory board member of Takeda. Chebli JMF has received fees for serving as a speaker and\/or an advisory board member for Takeda, Janssen, AbbVie, Abbott, and Sandoz. Magro, DO, Sales MPM, Barros LL, Sassaki LY, Flores C, Vieira A, Lubini M, Coy CSR, Zaltmann C, and F\u00e9res O report no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"184"}}